Outcomes of Allogeneic Hematopoietic Cell Transplantation in T Cell Prolymphocytic Leukemia: A Contemporary Analysis from the Center for International Blood and Marrow Transplant Research.
СтатьяПоддержка исследования: вне правительства СШАПоддержка NIH: внешняя программаПоддержка правительства СШАНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Murthy Hemant S, Ahn Kwang Woo, Estrada-Merly Noel, Alkhateeb Hassan B, Bal Susan, Kharfan-Dabaja Mohamed A, Dholaria Bhagirathbhai, Foss Francine, Gowda Lohith, Jagadeesh Deepa, Sauter Craig, Abid Muhammad Bilal, Aljurf Mahmoud, Awan Farrukh T, Bacher Ulrike, Badawy Sherif M, Battiwalla Minoo, Bredeson Chris, Cerny Jan, Chhabra Saurabh, Deol Abhinav, Diaz Miguel Angel, Farhadfar Nosha, Freytes César, Gajewski James, Gandhi Manish J, Ganguly Siddhartha, Grunwald Michael R, Halter Joerg, Hashmi Shahrukh, Hildebrandt Gerhard C, Inamoto Yoshihiro, Jimenez-Jimenez Antonio Martin, Kalaycio Matt, Kamble Rammurti, Krem Maxwell M, Lazarus Hillard M, Lazaryan Aleksandr, Maakaron Joseph, Munshi Pashna N, Munker Reinhold, Nazha Aziz, Nishihori Taiga, Oluwole Olalekan O, Ortí Guillermo, Pan Dorothy C, Patel Sagar S, Pawarode Attaphol, Rizzieri David, Saba Nakhle S, Savani Bipin, Seo Sachiko, Ustun Celalettin, van der Poel Marjolein, Verdonck Leo F, Wagner John L, Wirk Baldeep, Oran Betul, Nakamura Ryotaro, Scott Bart, Saber Wael
Аннотация
T cell prolymphocytic leukemia (T-PLL) is a rare, aggressive malignancy with limited treatment options and poor long-term survival. Previous studies of allogeneic hematopoietic cell transplantation (alloHCT) for T-PLL are limited by small numbers, and descriptions of patient and transplantation characteristics and outcomes after alloHCT are sparse. In this study, we evaluated outcomes of alloHCT in patients with T-PLL and attempted to identify predictors of post-transplantation relapse and survival. We conducted an analysis of data using the Center for International Blood and Marrow Transplant Research database on 266 patients with T-PLL who underwent alloHCT between 2008 and 2018. The 4-year rates of overall survival (OS), disease-free survival (DFS), relapse, and treatment-related mortality (TRM) were 30.0% (95% confidence interval [CI], 23.8% to 36.5%), 25.7% (95% CI, 20% to 32%), 41.9% (95% CI, 35.5% to 48.4%), and 32.4% (95% CI, 26.4% to 38.6%), respectively. In multivariable analyses, 3 variables were associated with inferior OS: receipt of a myeloablative conditioning (MAC) regimen (hazard ratio [HR], 2.18; P < .0001), age >60 years (HR, 1.61; P = .0053), and suboptimal performance status, defined by Karnofsky Performance Status (KPS) <90 (HR, 1.53; P = .0073). Receipt of an MAC regimen also was associated with increased TRM (HR, 3.31; P < .0001), an elevated cumulative incidence of grade II-IV acute graft-versus-host disease (HR, 2.94; P = .0011), and inferior DFS (HR, 1.86; P = .0004). Conditioning intensity was not associated with relapse; however, stable disease/progression was correlated with increased risk of relapse (HR, 2.13; P = .0072). Both in vivo T cell depletion (TCD) as part of conditioning and KPS <90 were associated with worse TRM and inferior DFS. Receipt of total body irradiation had no significant effect on OS, DFS, or TRM. Our data show that reduced-intensity conditioning without in vivo TCD (ie, without antithymocyte globulin or alemtuzumab) before alloHCT was associated with long-term DFS in patients with T-PLL who were age ≤60 years or who had a KPS >90 or chemosensitive disease.